Debora Rosa BUBLIK,Zelig ESHHAR,Salomon STEMMER,Izhak HAVIV,Guy ALLON,Ido BACHELET,Yoav BEN YAACOV,Nadav COHEN
申请号：
US16637503
公开号：
US20200215112A1
申请日:
2018.08.08
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention provides compositions and methods for improved T-cell therapy of cancer characterized by overexpression of Her2/neu oncogene. Provided are T cells capable of expressing or expressing chimeric antigen receptor (CAR) that specifically recognizes Her2/neu. These T cells have prolonged half-life in the blood circulation and enhanced cytotoxicity, and are used in treatment of a cancer characterized by overexpression of Her2/neu oncogene.
